Sigilon is developing an encapsulated cell therapy platform that combines advanced cell engineering with innovations in biocompatible materials to provide durable, controllable, and safe treatment for serious chronic diseases without generating immune rejection or fibrosis. The company was founded by Flagship Pioneering in conjunction with Robert Langer, Sc.D., and Daniel Anderson, Ph.D., of MIT in 2016. Sigilon is headquartered in Cambridge, MA.